PTC Therapeutics, Inc. (PTCT) News
Filter PTCT News Items
PTCT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PTCT News Highlights
- PTCT's 30 day story count now stands at 17.
- Over the past 24 days, the trend for PTCT's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- PTC, AADI and DE are the most mentioned tickers in articles about PTCT.
Latest PTCT News From Around the Web
Below are the latest news stories about Ptc Therapeutics Inc that investors may wish to consider to help them evaluate PTCT as an investment opportunity.
Aadi Bioscience Appoints Emma Reeve to its Board of DirectorsLOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Emma Reeve to its Board of Directors as Audit Committee Chair. Ms. Reeve brings over 25 years of value creation in pharmaceutical, medical device and bio-pharma service companies and a successful track record of transitioning companies from private to public. She currently sits on the boards of PTC Therapeutics (Nasdaq: PTCT) and privately-held Ribon Therapeutics and is Audit Committee Chair at both companies, and was recently appointed to the board of Editas Medicine (Nasdaq: EDIT). Most recently, Ms. Reeve was Chie... |
Duchenne Muscular Dystrophy Treatment Market to Witness Growth Acceleration by Top Key Players Like Santhera Pharmaceuticals, NS Pharma Inc., Bristol, PTC Therapeutics, Nobelpharma Co. Ltd, PfizerIntroduction: Duchenne Muscular Dystrophy (DMD) is muscle degeneration and is a genetic disorder which is X-linked recessive. However, it is also inherited from parents or caused due to a new mutation. There are various therapies and drugs to control DMD; however, |
PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient CommunityPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program. The global STRIVE Awards program provides grants to non-profit organizations serving the Duchenne muscular dystrophy community. |
Global Dravet Syndrome (DS) Market Analysis, Scope and Forecast By 2021-2027. The IBI Updates I Top key players-Ovid Therapeutics/Takeda, PTC Therapeutics and Zogenix & OthersThe research provided by Infinity Business Insights provides a thorough explanation of the disease as well as DS market trends in several locations. It examines multiple studies and the perspectives of important opinion leaders to assist identify the reasons of |
PTC Therapeutics to Participate at Upcoming Virtual Investor ConferencesPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: |
Angelman Syndrome Market Will Hit Big Revenues in Upcoming Future by 2028| Ovid Therapeutics, GeneTx Biotherapeutics, PTC Therapeutics, Sarepta Therapeutics and StrideBioAngelman syndrome is a genetic condition that affects the nervous system and causes severe physical and learning disabilities. A person with Angelman syndrome will have a near-normal life expectancy, but they will need support throughout their life. Angelman syndrome can result |
PTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic DisorderThe Brazilian Health Regulatory Agency has approved PTC Therapeutics Inc's (NASDAQ: PTCT) Waylivra (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS). The approval is based on the Phase 3 APPROACH study results and the APPROACH Open-Label Extension study and is supported by results from the Phase 3 COMPASS study. Results from the Phase 3 APPROACH trial showed that the treatment reduced triglycerides by 94% compared to placebo. All patients in the trial maintained a |
PTC Therapeutics Announces Waylivra Approval in Brazil as First Treatment for Familial Chylomicronemia SyndromeSOUTH PLAINFIELD, N.J. , Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS) in Brazil . FCS is a rare genetic disease which results in significant disease burden to patients including potentially fatal pancreatitis and chronic complications due to permanent organ damage. "We are excited to announce Waylivra''s approval in Brazil as the first treatment for the underlying cause of FCS," said Stuart W. Peltz , Ph.D., Chief Executive Officer, PTC Therapeutics. "This approval is another example of PTC leveraging its strong capabilities in Latin America to bring ... |
PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia SyndromePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS) in Brazil. FCS is a rare genetic disease which results in significant disease burden to patients including potentially fatal pancreatitis and chronic complications due to permanent organ damage. |
Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC DeficiencyPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, "Gene Therapy in the Putamen for Curing AADC Deficiency and Parkinson's Disease," in the European Molecular Biology Organization Journal. The paper describes a pioneering approach that delivers gene therapy to a specific part of the brain called the putamen, which is helping successfully treat a previously intractable, devastating disorder and transforming the lives of children born with AADC deficiency (AADC- |